EWING SARCOMA

Ewing Sarcoma is a rare, aggressive, and highly malignant tumor that originates in bone or soft tissues. It is classified as a type of bone cancer but can also occur in extraosseous (non-bone) locations like muscle, fat, and connective tissue.

Ewing Sarcoma belongs to a family of tumors known as the Ewing Sarcoma Family of Tumors (ESFT), which includes:

• Classic Ewing Sarcoma of bone
• Extraosseous Ewing Sarcoma (in soft tissues)
• Peripheral Primitive Neuroectodermal Tumor (pPNET)
• Askin tumor (in the chest wall)

It typically affects children, adolescents, and young adults between the ages of 5 and 25 years, with a peak incidence in teenage years. Ewing Sarcoma is the second most common bone cancer in children, after osteosarcoma.

CAUSES AND RISK FACTORS

The exact cause of Ewing Sarcoma is unknown, but several genetic and environmental factors contribute:

Genetic Causes:

• Chromosomal Translocations: In 85% of cases, a specific translocation occurs between chromosomes 11 and 22 (t(11;22)(q24;q12)), creating an EWSR1-FLI1 fusion gene. This abnormal gene triggers uncontrolled cell growth.
• Other Translocations: In a minority of cases, fusions involve EWSR1 and other genes like ERG, ETV1, FEV, or E1AF.

Risk Factors:

• Age: Most common in children and adolescents (10-20 years).
• Gender: Slightly more prevalent in males than females.
• Ethnicity: More common in people of European descent. Rare in African and Asian populations.
• Family History: No clear inherited pattern, though rare genetic syndromes may increase risk.
• Radiation Exposure: A weakly associated factor in rare cases.

SYMPTOMS

Symptoms vary based on tumor location and size but commonly include:

Bone Symptoms:

• Persistent, progressive pain in the affected area
• Swelling, redness, or a visible lump
• Localized warmth over the tumor site
• Bone fractures without trauma (pathological fractures)

Systemic Symptoms:

• Fever
• Fatigue
• Weight loss
• Anemia (due to marrow involvement)
• Night sweats (in some cases)

Common Sites:

• Pelvis (most frequent)
• Femur (thigh bone)
• Tibia (shin)
• Ribs (Askin tumor)
• Humerus (upper arm)
• Spine (rare)

DIAGNOSIS

Early and accurate diagnosis is vital for improving outcomes.

Clinical Evaluation:

• History of bone pain, swelling, and systemic symptoms
• Physical exam for swelling, tenderness, or mass

Diagnostic Tests:

• X-ray: Reveals “onion skin” (lamellated) or “moth-eaten” bone appearance.
• MRI: Best for defining soft tissue involvement and marrow infiltration.
• CT scan: Detects bone destruction and metastases.
• Bone scan: Highlights metastatic spread to other bones.
• PET-CT: Assesses local and distant metastases.
• Biopsy: Confirmatory test. Histology shows small, round, blue cells.
• Immunohistochemistry: Positive for CD99 (MIC2) antigen in most cases.
• Genetic Testing (FISH/RT-PCR): Detects EWSR1-FLI1 translocation.

STAGING

The American Joint Committee on Cancer (AJCC) uses a TNM system for staging.

PREVENTION & EARLY DETECTION

Ewing Sarcoma cannot currently be prevented, as its cause is largely genetic and unrelated to lifestyle.

Early detection through awareness of symptoms (persistent bone pain, swelling) and prompt medical evaluation can improve outcomes.

TREATMENT FOR EWING SARCOMA

Treatment requires a multimodal approach combining chemotherapy, surgery, and/or radiotherapy.

Chemotherapy (Primary Treatment):

Given before (neoadjuvant) and after (adjuvant) local control measures:

• Drugs used:
  • Vincristine
  • Doxorubicin
  • Cyclophosphamide
  • Ifosfamide
  • Etoposide

Regimen example: VDC-IE (Vincristine, Doxorubicin, Cyclophosphamide alternating with Ifosfamide, Etoposide)

Surgery:

Preferred for local tumor control:

• Wide surgical excision with negative margins
• Limb-sparing surgeries favored over amputation
• Pelvic and spine tumors may require complex surgery

Radiation Therapy:

Used when:

• Complete surgical removal isn’t feasible
• To treat residual disease
• For palliation in metastatic cases

High-Dose Chemotherapy with Stem Cell Rescue

Considered in select metastatic or relapsed cases.

PROGNOSIS

Ewing Sarcoma is aggressive, but prognosis has improved with multimodal therapy.

Prognostic Factors:

• Tumor size and location
• Presence of metastasis at diagnosis
• Histological response to chemotherapy
• Age (younger patients fare better)

FOOD & DIET FOR EWING SARCOMA PATIENTS

While no diet cures Ewing Sarcoma, good nutrition supports recovery, immunity, and therapy tolerance.

Recommended Foods:

• Lean proteins: Eggs, fish, chicken, legumes
• Whole grains: Oats, quinoa, brown rice
• Antioxidant-rich fruits and vegetables
• Omega-3-rich foods: Salmon, walnuts
• Probiotics: Yogurt, kefir
• Hydrating fluids: Water, herbal teas

Foods to Avoid:

• Processed meats and snacks
• Sugary beverages
• Deep-fried foods
• Excessive sodium
• Excess alcohol

Immune-Boosting Nutrients:

• Vitamin C: Citrus, bell peppers
• Vitamin E: Almonds, sunflower seeds
• Zinc: Pumpkin seeds, lentils
• Selenium: Brazil nuts
• Vitamin D: Fortified milk, sunlight exposure

FAQs

1. Can Ewing Sarcoma spread to the lungs?

   Yes — the lungs are the most common site for metastasis.

2. Is Ewing Sarcoma curable?

   Yes, if localized and treated early. Metastatic disease is harder to cure but treatable.

3. How fast does Ewing Sarcoma grow?

   Very fast — often noticeable growth within weeks to months.

4. Can it affect adults?

   Yes, but it’s rare after age 30.

5. Are there clinical trials for Ewing Sarcoma?

   Yes — new immunotherapy, targeted therapy, and gene therapy trials are ongoing.

6. What is the risk of recurrence?

   Up to 30–40% for localized cases; higher for metastatic disease.

7. Can Ewing Sarcoma return years later?

   Relapses often occur within 2 years, but late recurrences (after 5 years) can happen.